20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Xeris Pharmaceuticals Inc (XERS) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Chicago, United States with about 435 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, XERS reported $292M in revenue and $1M in net income.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.
Interactive charts & full statements → Open the XERS valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $335M | $292M | $203M | $164M | $110M | $50M | $3M | $3M | $2M | $2M | $1M |
| Gross Profit | $280M | $238M | $166M | $135M | $88M | $36M | $1M | $1M | $2M | $2M | $1M |
| Gross Margin % | 83.6% | 81.7% | 81.9% | 82.5% | 79.5% | 73.1% | 41.1% | 41.1% | 98.3% | 99.7% | 99.3% |
| Operating Income (EBIT) | $37M | $25M | ($34M) | ($44M) | ($82M) | ($115M) | ($122M) | ($122M) | ($59M) | ($27M) | ($13M) |
| Operating Margin % | 11.0% | 8.5% | -16.6% | -26.9% | -74.3% | -232.2% | -4496.0% | -4496.0% | -2407.5% | -1711.4% | -1230.8% |
| Net Income | ($17M) | $1M | ($55M) | ($62M) | ($95M) | ($123M) | ($126M) | ($126M) | ($60M) | ($27M) | ($13M) |
| Net Margin % | -5.1% | 0.2% | -27.0% | -38.0% | -85.9% | -247.5% | -4613.5% | -4613.5% | -2437.3% | -1706.6% | -1228.7% |
| EBITDA | $16M | $13M | ($14M) | ($24M) | ($69M) | ($114M) | ($118M) | ($120M) | ($57M) | ($26M) | ($13M) |
| Earnings Per Share (EPS) | $-0.11 | $0.00 | $-0.37 | $-0.45 | $-0.70 | $-1.55 | $-4.81 | $-4.81 | $-4.99 | $-13.09 | $-7.17 |
| Shares Outstanding (M) | 173M | 173M | 147M | 138M | 136M | 79M | 26M | 26M | — | 2M | 2M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $92M | $83M | $86M | $74M | $72M | $60M | $60M | $54M |
| Gross Profit | $80M | $70M | $67M | $63M | $57M | $51M | $51M | $41M |
| Gross Margin % | 86.4% | 84.0% | 77.8% | 85.2% | 79.6% | 85.5% | 84.2% | 75.0% |
| Operating Income (EBIT) | $5M | $8M | $17M | $7M | $4M | ($3M) | $2M | ($13M) |
| Operating Margin % | 5.6% | 9.5% | 19.6% | 9.0% | 6.3% | -5.1% | 2.8% | -23.8% |
| Net Income | ($31M) | $2M | $11M | $1M | ($2M) | ($9M) | ($5M) | ($16M) |
| Net Margin % | -33.8% | 2.7% | 12.9% | 0.8% | -2.7% | -15.3% | -8.5% | -29.0% |
| EBITDA | ($21M) | $12M | $14M | $11M | $9M | $1M | $6M | ($8M) |
| Earnings Per Share (EPS) | $-0.18 | $0.01 | $0.06 | $0.00 | $-0.01 | $-0.06 | $-0.03 | $-0.11 |
| Shares Outstanding (M) | 173M | 178M | 180M | 178M | 156M | 152M | 149M | 149M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $56M | $29M | ($37M) | ($47M) | ($103M) | ($96M) | ($81M) | ($104M) | ($56M) | ($25M) | ($16M) |
| Capital Expenditures (CapEx) | $0M | $1M | $1M | $2M | $1M | $1M | $0M | $1M | $2M | $1M | $0M |
| Free Cash Flow (FCF) | $56M | $28M | ($38M) | ($49M) | ($103M) | ($97M) | ($81M) | ($105M) | ($58M) | ($25M) | ($16M) |
| FCF Margin % | 16.7% | 9.6% | -18.6% | -30.1% | -93.8% | -194.8% | -2973.4% | -3874.1% | -2344.4% | -1630.0% | -1499.7% |
| Dividends Paid | — | — | — | — | $147M | $25M | $96M | $61M | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $8M | $10M | $20M | $18M | $0M | ($10M) | $2M | ($8M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | $8M | $10M | $20M | $18M | $0M | ($10M) | $2M | ($8M) |
| FCF Margin % | 8.7% | 11.5% | 23.0% | 24.3% | -0.1% | -16.7% | 2.9% | -15.5% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $412M | $384M | $323M | $323M | $345M | $304M | $109M | $109M | $120M | $45M | $34M |
| Cash & Cash Equivalents | $122M | $111M | $72M | $67M | $122M | $67M | $20M | $20M | $46M | $42M | $32M |
| Total Liabilities | $422M | $370M | $353M | $329M | $299M | $209M | $95M | $95M | $45M | $103M | $65M |
| Total Debt (Short + Long-Term) | $259M | $227M | $238M | $194M | $189M | $90M | $87M | $58M | $40M | $3M | $1M |
| Total Shareholders' Equity | ($10M) | $14M | ($30M) | ($7M) | $45M | $95M | $14M | $14M | $75M | ($58M) | ($32M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive XERS viewer.
About TickerBase · Data methodology & sources · Privacy · Terms